BioPharma Resources

Drug Trial Radar · NCT07896252

Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients

Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment With Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Administered Via Nebulization in Participants With Chronic Obstructive Pulmonary Disease (COPD) (AERODUO-2 Trial)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Jun 2027

Study completion Sep 2027

Sponsor

Lead sponsor
AeroRx Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).

Conditions

  • COPD
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Lung Disease Chronic
  • Lung Diseases, Obstructive

Interventions

  • AERO-001Drug

    Double-blind

  • AERO-002Drug

    Double-blind

  • AERO-007Drug

    Double-blind

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bronchodilation - FEV1Time frame: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
  2. Bronchodilation - FEV AUCTime frame: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
  3. Bronchodilation - Peak FEV1Time frame: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
  4. Bronchodilation - time to onset of FEV1 >100mLTime frame: Change in FEV1 >100mL from pre-dose on Days 1 and 14

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Parexel

    London, United Kingdom · Recruiting

  • Medicines Evaluation Unit

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.